In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Added value of computed tomography fractional flow reserve (FFRCT) in the diagnosis of coronary artery disease (CAD)

Session Poster Session 7

Speaker Joyce Peper

Congress : ESC Congress 2019

  • Topic : imaging
  • Sub-topic : CT-derived FFR
  • Session type : Poster Session
  • FP Number : P6176

Authors : J Peper (Nieuwegein,NL), J Schaap (Breda,NL), JC Kelder (Nieuwegein,NL), DE Grobbee (Utrecht,NL), MJ Swaans (Nieuwegein,NL)

Authors:
J Peper1 , J Schaap2 , JC Kelder1 , DE Grobbee3 , MJ Swaans1 , 1St Antonius Hospital - Nieuwegein - Netherlands (The) , 2Amphia Hospital - Breda - Netherlands (The) , 3University Medical Center Utrecht - Utrecht - Netherlands (The) ,

Citation:

Purpose
Multiple non-invasive tests are performed as part of the standard protocol to diagnose CAD, but all are limited to either anatomical or functional assessments. FFRCT is a new non-invasive test that combines anatomical and functional characteristics based on the principles of invasive FFR. This study aims to evaluate the added value of FFRCT beyond the currently used tests.

Methods
Patients having the clinical suspicion of angina pectoris between 2010 and 2011 were included in this cross-sectional study. All underwent exercise stress electrocardiography (X-ECG), SPECT, CT coronary angiography (CCTA) and FFRCT as part of the Horoscope study. Invasive coronary angiography(ICA) and FFR were used as reference standard. Missing values were multiple imputed and five combined models mimicking the clinical workflow were fitted. The area under the receiver operating characteristic (AUROC) curve and Akaike Information Criteria (AIC) were used for comparison.

Results
89 (44%) of the 202 patients included in the analysis had a FFR of =0.80, while positive tests were found for X-ECG, SPECT, CCTA and FFRCT in 41%, 47%, 53% and 50% of the cases. The model including pre-test-likelihood and X-ECG  had an AUROC of 0.78 (AIC: 236), which significantly increases to 0.89 by adding SPECT (AIC: 170), to 0.87 by adding CCTA (AIC: 191), to 0.92 when adding FFRCT (AIC: 155) and to 0.94 when adding CCTA and SPECT(AIC:1 40).

Conclusion
This study shows adding FFRCT  leads to an increased AUROC and a decreased AIC compared to the basic model. It therefore improves the diagnostic work-up beyond SPECT or CCTA alone in the diagnosis of CAD.

Model 1

Model 2

Model 3

Model 4

Model 5

Basic model

+ SPECT

+ CCTA

+ CCTA

+ FFRCT

+SPECT

+ CCTA

AIC

236.0

169.8

190.8

154.5

140.1

AUC

0.78

0.89

0.87

0.92

0.94

ROC-curves for all diagnostic models and its AIC and AUC. FFRCT has an improved AUC compared to the basic model and the models including SPECT or CCTA alone, while its AIC is decreased. The model including both SPECT and CCTA has the highest AUC and the lowest AIC and seems therefore the preferable strategy.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are